| Literature DB >> 30515798 |
Nasser Hashemi Goradel1, Nasir Mohajel2, Ziba Veisi Malekshahi1, Samira Jahangiri3, Masoud Najafi4, Bagher Farhood5, Keywan Mortezaee6, Babak Negahdari1, Arash Arashkia2.
Abstract
Cancer therapy using oncolytic viruses is an emerging area, in which viruses are engineered to selectively propagate in tumor tissues without affecting healthy cells. Because of the advantages that adenoviruses (Ads) have over other viruses, they are more considered. To achieve tumor selectivity, two main modifications on Ads genome have been applied: small deletions and insertion of tissue- or tumor-specific promoters. Despite oncolytic adenoviruses ability in tumor cell lysis and immune responses stimulation, to further increase their antitumor effects, genomic modifications have been carried out including insertion of checkpoint inhibitors and antigenic or immunostimulatory molecules into the adenovirus genome and combination with dendritic cells and chemotherapeutic agents. This study reviews oncolytic adenoviruses structures, their antitumor efficacy in combination with other therapeutic strategies, and finally challenges around this treatment approach.Entities:
Keywords: adenovirus; dendritic cells; immune responses; oncolytic viruses; tumor
Mesh:
Substances:
Year: 2018 PMID: 30515798 DOI: 10.1002/jcp.27850
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384